The Effect of Gel Secretome Hypoxia Mesenchymal Stem Cells to Increase P38 and VEGF Expression in Rats’ Diabetic Wounds
Syamsunarno M.R.A.A., Putra A., Hasannuri T.R.
Abstract
Mesenchymal stem cells (MSCs) under hypoxic conditions can produce secretomes containing growth factors such as vascular endothelial growth factor (VEGF), accelerating angiogenesis in wound healing disorders in diabetic ulcers. This study aimed to prove the influence of gel secretome MSC hypoxia administration on increasing VEGF and P38 gene expression in rats’ diabetic wounds. An in vivo study was conducted on 25 male Rattus norvegicus, randomly divided into four groups: base gel as a negative control, Gentamycin as a positive control, and gel secretome at a dose of 100 µL, and 200 µL/kg body weight. The differences in P38 and VEGF gene expression were tested using quantitative real-time polymerase chain reaction (qRT-PCR). Wound closure appeared to be fastest in treatment groups at a dose of 100 µL/kg body weight, followed by a dose of 200 µL/kg body weight, followed by Gentamycin and base gel group. The wound closure rate percentage was significantly different in the intervention group compared to the control group (p = 0.000). The results showed a significant difference in P38 and VEGF gene expression between the treatment and control groups (p = 0.000). This study demonstrates the administration of gel secretome hypoxia mesenchymal stem cells increases P38 and VEGF expression in rats’ diabetic wounds.
PPAR-γpromotes p38 MAP kinase-mediated endothelial cell permeability through activating Sirt3
Dai Y., Deng Y., Meng Y., Pan K., Xu T., Zhang X., Zhao Z.
Diabetic ulcer regeneration: stem cells, biomaterials, growth factors
Eatemadi A., Eatemadi A., Negahdari B., Zarei F.
Advanced Glycation End Products Impair Glucose-Stimulated Insulin Secretion of a Pancreatic β-Cell Line INS-1-3 by Disturbance of Microtubule Cytoskeleton via p38/MAPK Activation
Deng T., Fang Q., Liu H., Lou J., Peng L., Wang Z., Xu S., You J., Zhang W.
Hypoxia-Conditioned Mesenchymal Stem Cells in Tissue Regeneration Application
Lee E.H., Lee E.H., Yang Y., Yang Y., Yang Z., Yang Z.
Therapeutic Use of Mesenchymal Stromal Cells: The Need for Inclusive Characterization Guidelines to Accommodate All Tissue Sources and Species
Arthaud-Day M.L., Weiss M.L., Wright A., Arthaud-Day M.L., Weiss M.L., Wright A.
A central role for p38 MAPK in the early transcriptional response to stress
Whitmarsh A.J.
Mesenchymal Stem/Stromal Cell Senescence: Hallmarks, Mechanisms, and Combating Strategies
Li B., Li L., Liu H., Ouchi T., Qiao X., Wang Y., Weng Z., Wu C., Zhao Z.
Using carbomer-based hydrogels for control the release rate of diclofenac sodium: Preparation and in vitro evaluation
Minhas M.U., Suhail M., Wu P.-C., Wu P.-C.
Bioactive antimicrobial peptides as therapeutic agents for infected diabetic foot ulcers
Carvalho E., Carvalho E., Leal E.C., Leal E.C., Silva J.D., Silva J.D., Silva J.D.
Migration of human umbilical cord blood mesenchymal stem cells mediated by stromal cell-derived factor-1/CXCR4 axis via Akt, ERK, and p38 signal transduction pathways
Jeong C.H., Jeun S.-S., Jeun S.-S., Jun J.A., Kim S.M., Lim J.Y., Oh J.H., Oh W.-I., Park S.A., Park S.H., Ryu C.H.
